What is the impact of excipients on tigecycline's bioavailability?

Short answer

In the marketed IV formulation of tigecycline, the excipients (primarily polysorbate 80, glycerol, sodium chloride and a acetate buffer) are deliberately chosen to keep the drug in a stable, soluble form so that every administered dose is effectively delivered into the bloodstream (≈ 100 % bioavailability). If excipients fail to keep the solution properly stabilized or if they promote precipitation (e.g., by chelating calcium or magnesium), the actual amount that reaches systemic circulation can fall well below the intended dose.

Because tigecycline is almost completely insoluble in water and is not absorbed from the gut, the oral formulation relies on excipients to improve dissolution—but even with the best excipients, oral bioavailability remains < 2 %. Thus, for IV administration the impact of excipients is largely stability‑/solubility‑related rather than “enhancement” of absorption.

1. What excipients are in the marketed IV product?

These excipients together keep tigecycline in a clear, stable, and non‑precipitating solution at 5 °C (refrigerated) until infusion.

2. How do these excipients influence bioavailability?

a. Stability and solubility

• pH control: Tigecycline is most stable around pH 5.4–5.5. The acetate buffer keeps the solution within this window, preventing hydrolysis or de‑protonation that would otherwise precipitate the drug.
• Surfactant action: Polysorbate 80 prevents aggregation of the glycylcycline moiety, keeping the drug in a monomeric, soluble form that can be readily absorbed into circulation.
• Humectant: Glycerol maintains viscosity and prevents the drug from adsorbing onto the vial or tubing surfaces.

If the excipient balance is wrong (e.g., too low surfactant or a higher pH), tigecycline can precipitate or degrade, leading to a lower effective dose that actually reaches systemic circulation.

b. Prevention of ion‑mediated precipitation

Tigecycline can form stable complexes with divalent cations (Ca²⁺, Mg²⁺, Fe²⁺). In the IV infusion bag, the presence of these ions (from the patient's own plasma or from calcium‑containing IV solutions) can precipitate the drug. The formulation’s buffer and surfactants mitigate this, but when the drug is co‑infused with calcium or magnesium salts, precipitation can occur. This is why clinical guidelines advise that tigecycline should not be mixed with calcium‑containing solutions, or at least that the infusion lines be separated.

c. Effect on pharmacokinetics

• Distribution: A stable, fully soluble infusion ensures that the drug’s pharmacokinetics are driven solely by its own properties (volume of distribution ≈ 40 L, protein binding ~ 30 %). Any reduction in effective dose (via precipitation) would shift the PK profile, potentially leading to sub‑therapeutic concentrations.
• Clearance: The IV route bypasses first‑pass metabolism; excipient‑related degradation before reaching the bloodstream would effectively reduce clearance calculations and alter dosing recommendations.

3. Why oral excipients do not dramatically change bioavailability

Tigecycline is a large, amphipathic molecule that is a strong substrate for efflux pumps (P‑gp, BCRP) in the intestine and has a low aqueous solubility. Even when formulated with excipients such as:

• Solid‑state enhancers (e.g., micro‑crystalline cellulose, povidone)
• Surfactants (e.g., sodium lauryl sulfate, polysorbate 80)
• pH modifiers (e.g., sodium bicarbonate, citric acid)

the maximum absorption achievable remains below 2 %. The drug’s poor permeability and efflux overwhelm any dissolution advantage. This is why tigecycline is available only IV for systemic therapy; the oral product is primarily used as an adjunct for enteral de‑contamination (e.g., in a “treatment” setting for a patient already on IV tigecycline, a low‑dose oral product may help maintain mucosal coverage).

4. Clinical implications of excipient–drug interactions

5. Bottom line for pharmacists and clinicians

1. Use the approved IV formulation: The excipients are specifically calibrated to provide 100 % bioavailability.
2. Avoid mixing with incompatible solutions: Calcium or magnesium salts, high‑pH solutions, or strong chelators can precipitate tigecycline.
3. Monitor for infusion reactions: Polysorbate 80 can trigger hypersensitivity.
4. Understand that oral formulations cannot overcome intrinsic permeability barriers: Excipients help dissolve but will not significantly raise oral bioavailability.

If you need to adjust the formulation for a special patient (e.g., severe renal impairment, long‑term therapy), consider the excipients’ impact on the drug’s stability and the patient’s overall tolerance rather than expecting a